Monteris Medical Announces College of Neurological Surgeons Guidelines Issued on Laser Interstitial Thermal Therapy for the Treatment of Adults with Metastatic Brain Tumors

The evidence-based guideline revision underscores the expanded use of LITT in metastatic disease

MINNETONKA, Minn., April 1, 2025 /PRNewswire/ -- Monteris Medical announced today that the College of Neurological Surgeons (CNS) has issued clinical guidelines supporting the use of laser interstitial thermal therapy (LITT) for adults with progressive metastatic brain tumors, post-stereotactic radiosurgery (SRS). These evidence-based recommendations highlight minimally invasive LITT as an option for patients experiencing tumor progression and radiation necrosis, an inflammatory response to SRS treatments.

The clinical guideline updates add to the well-established body of clinical evidence and existing recommendations, including those from the National Comprehensive Cancer Network (NCCN^®), further supporting the role of LITT in neuro-oncology. The guideline revisions also underscore the expanded use of LITT in metastatic disease in recent years and align with the anticipated Level I evidence from Monteris' own REMASTer randomized controlled trial. REMASTer is examining early intervention with LITT for radiographic progression in brain metastases previously treated with radiosurgery.

"This represents an important validation that minimally invasive LITT is a critical tool for practicing neurosurgeons facing the radiographic progression conundrum in the treatment of patients with brain metastases," said Dr. Adrian Laxton, professor of neurological surgery and REMASTer principal investigator at Wake Forest University School of Medicine in Winston-Salem, N.C. "The REMASTer trial aims to characterize the optimal timing of early identification and intervention in this complex patient population."

The CNS guidelines state that LITT should be considered equivalent to open craniotomy in terms of progression-free and overall survival for adults with radiographic progression in metastatic tumors following SRS. Additionally, for patients who have undergone SRS for brain metastases and later experience imaging progression due to radiation necrosis, LITT is recommended as an equivalent alternative to medical management.

"The recognition by CNS that LITT is indispensable for neurosurgical programs, in addition to its endorsement for brain metastases patients, accentuates the substantial contributions of clinical evidence that Monteris and our physician partners have made over the years," stated Martin J. Emerson, president and chief executive officer of Monteris Medical. "The updates to CNS and NCCN guidelines, respectively, firmly establish LITT as a critical component in the care of brain tumor patients and emphasize our unwavering commitment to advancing LITT technology through our NeuroBlate^® System."

About REMASTer (NCT05124912)

REMASTer (Recurrent Brain Metastases After SRS Trial) is a randomized post-market multi-center study designed to investigate LITT with the NeuroBlate System as an early intervention for radiographically progressive brain metastases following SRS and to provide Level I evidence to guide treatment for this patient population. The study is currently enrolling at nine sites. Study information is located here: https://clinicaltrials.gov/study/NCT05124912

About Monteris and the NeuroBlate System

Monteris Medical is a privately held company that develops and markets innovative MR-guided ablation systems to perform minimally invasive, robotically controlled brain surgery, commonly referred to as laser ablation, LITT (Laser Interstitial Thermal Therapy) or SLA (Stereotactic Laser Ablation). The Monteris NeuroBlate System is the only minimally invasive system that enables a robotic interface for the precise and safe delivery of laser energy. The Monteris Medical NeuroBlate System is a neurosurgical tool and is intended for ablating intracranial soft tissue, including brain structures such as brain tumors, radiation necrosis, and epileptic foci (as identified by non-invasive and invasive neurodiagnostic testing, including imaging) in adults and pediatric patients aged 2 years and over. For more information, visit monteris.com.

Contact:
Doug Pahr
Chief Financial Officer
[email protected]
763-253-4710

SOURCE Monteris Medical